Ocriplasmin

CHEMBL2095222 Phase 4 Zugelassen Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

An enzyme injected into the eye to treat a condition called symptomatic vitreomacular adhesion, where the gel-like substance inside the eye pulls abnormally on the retina. It helps dissolve the protein attachments causing this traction, potentially avoiding the need for surgery.

Therapeutische Bereiche

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An enzyme injected into the eye to treat a condition called symptomatic vitreomacular adhesion, where the gel-like substance inside the eye pulls abnormally on the retina. It helps dissolve the protein attachments causing this traction, potentially avoiding the need for surgery.

Yes, Ocriplasmin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2095222. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.